Argentina vs Georgia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Argentina
79.0%
in 2025
Georgia
77.0%
in 2025
Argentina rank
119th
Georgia rank
122nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Argentina
- Georgia
How they compare
Argentina currently reports 79.0% against 77.0% in Georgia, a difference of 2.0%.
The two have swapped places 5 times across 18 shared years of data; in 2008 it was Georgia ahead.
Argentina ranks 119th and Georgia ranks 122nd of 192 countries.
Across the 3 decades both report, Argentina averaged higher in 1 and Georgia in 1.
Head to head by decade
| Decade | Argentina | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 62.6% | 33.6% | 29.0% | Argentina |
| 2020s | 77.0% | 81.3% | 4.3% | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Argentina or Georgia?
- Argentina, at 79.0% against 77.0% in Georgia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Argentina and Georgia?
- 2.0%, with Argentina ahead.
- How many years of comparable data are there for Argentina and Georgia?
- 18 years are reported by both, from 2008 to 2025.
- How do Argentina and Georgia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Argentina ranks 119th and Georgia ranks 122nd of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.